Summary of the Conference Call for BaiO SaiTu Company Overview - BaiO SaiTu, established in 2009, is a publicly listed company in Hong Kong and A-shares, headquartered in Beijing with animal production centers in Jiangsu and a research base in Boston, USA [3][4] - The company operates two core business lines: "Model Organisms" and "Thousand Mice and Ten Thousand Antibodies" [3] Financial Performance - In 2025, BaiO SaiTu achieved revenue of 1.378 billion yuan (+41%) and net profit of 173 million yuan (+400%), marking a profitability turning point [2][4] - Operating cash flow reached 370 million yuan (+75%) [2] - The company expects a compound annual growth rate (CAGR) of at least 35% from 2026 to 2028 [2] Business Segments Preclinical Business - Revenue from preclinical services (including animal model sales and CRO services) was approximately 1 billion yuan (+58%) in 2025, with a gross margin of over 70% [4][5] - The growth in pharmacological services was particularly rapid, with the company serving global top 10 pharmaceutical companies [5] Antibody Business - The "Thousand Mice and Ten Thousand Antibodies" business generated 330 million yuan in revenue in 2025, maintaining a gross margin of over 80% [5] - The company anticipates milestone revenue from antibody projects to reach 100 million yuan in 2026, with over 10 molecules expected to enter clinical or IND stages [4][10] Technological Advancements - The RenSuper-AI platform, launched in March 2026, aims to enhance antibody transfer efficiency by 5-20 times through AI predictions and automated wet experiments [2][8] - The company has developed over 1 million high-quality antibody sequences since the initiation of the "Thousand Mice and Ten Thousand Antibodies" program [5][12] Market Dynamics - The demand for model organisms, particularly humanized mice, is expected to grow at a rate of no less than 15% annually, driven by the expansion of application scenarios and the increasing complexity of drug molecules [6][23] - BaiO SaiTu aims to capture over 50% of the global market share in innovative animal models, leveraging its technological advantages and established production systems [22][23] Global Expansion - The company has focused on global expansion, particularly in the U.S. market, where it has maintained a 60% CAGR in overseas business from 2023 to 2025 [7] - Overseas revenue accounted for approximately 70% of total revenue, with significant contributions from top global pharmaceutical companies [7] Capacity Expansion - A new facility in Jiangsu, covering 15,000 square meters, is expected to be operational by Q3 2026, adding 120,000 cage positions (+40%) to meet growing demand [18] - Plans for a new 90,000 to 100,000 square meter facility are underway to support GLP services and global exports by 2028 [18] Cost Management - The company plans to reduce R&D expense ratio from 30% to around 25% while ensuring profit growth outpaces revenue growth [4][19] - Financial expenses are expected to decrease significantly in 2026 [4][19] Future Outlook - BaiO SaiTu's strategic development is divided into two phases: 2020-2024 focused on technology foundation and 2025-2028 aimed at harvesting the results of previous investments [9] - The company anticipates rapid profit release, particularly from milestone payments starting in 2026 [10][24] Conclusion - BaiO SaiTu is positioned to leverage its technological advancements, global market presence, and strategic planning to drive significant growth in the coming years, particularly in the antibody and preclinical service sectors [26][27]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 百奧賽圖（北京）醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2315） 海外監管公告 本公告乃百奧賽圖（北京）醫藥科技股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條的規定刊發。 茲載列本公司於上海證券交易所網站刊發的以下公告，僅供參閱。 1 1. 百奧賽圖（北京）醫藥科技股份有限公司2025年年度報告 2. 百奧賽圖（北京）醫藥科技股份有限公司2025年年度報告摘要 3. 百奧賽圖（北京）醫藥科技股份有限公司2025年度環境、社會和公司治理 (ESG)報告 4. 百奧賽圖（北京）醫藥科技股份有限公司2025年度環境、社會和公司治理 (ESG)報告摘要 5. 百奧賽圖（北京）醫藥科技股份有限公司2025年度利潤分配方案公告 6. 百奧賽圖（北京 ...

Group 1 - The Hang Seng Index rose by 0.92%, gaining 245 points to close at 27,094, while the Hang Seng Tech Index increased by 1.54% [1] - Zhipu (02513) surged over 16% after launching the first domestic chip training multimodal SOTA model in collaboration with Huawei [1] - Alibaba (09988) saw a rise of over 5% as it significantly increased its capital expenditure budget for Alibaba Cloud, with institutions expecting earnings resilience to exceed expectations [1] - Alibaba Health (00241) jumped over 15% after the exclusive launch of Beimei Jing, which received the first overseas drug price certification [1] - Yidu Tech (02158) rose over 9% after winning first place in a smart healthcare innovation competition, showcasing its strong AI medical innovation capabilities [1] Group 2 - Tongdao Liepin (06100) soared over 10% due to deepening AI strategy and stable financials leading to market revaluation [2] Group 3 - Baiaosaitu-B (02315) increased over 6% after completing the localization of its AI-driven antibody drug development platform [3] - Maifushi (02556) rose over 8%, with its stock price nearly doubling in the past three weeks after launching the GEO smart assistant [3] - MicroPort Robotics-B (02252) gained over 8%, as the surgical robot industry is expected to enter a commercialization and policy acceleration phase [3] - Hua Hong Semiconductor (01347) increased over 5%, with Goldman Sachs noting high capacity utilization supporting product mix optimization and price increases [3] - Restaurant stocks led the gains, with institutions expecting most leading restaurant brands to see a recovery in customer traffic, leading to more rational competition [3] - Haidilao (06862) rose by 7%, while Jiumaojiu (09922) increased by over 5% [3] Group 4 - Qiutai Technology (01478) saw a 13% increase after issuing a profit warning, expecting a 400% to 450% year-on-year growth in comprehensive profit for the fiscal year 2025 [4]

Core Insights - The article highlights the rapid development of Hong Kong's biotechnology industry, driven by collaboration with mainland China and innovative companies like Yuanhua Intelligent Technology and China Antibody Pharmaceutical Company [1][5][6] Company Summaries - Yuanhua Intelligent Technology, founded in 2018, specializes in high-end intelligent medical equipment and has successfully completed over 5,000 surgeries using its surgical robots [3][5] - China Antibody Pharmaceutical Company focuses on antibody drug development and has established strategic partnerships to enhance its research capabilities and expedite the commercialization of its products [5][6] Industry Trends - The number of biotechnology-related companies in Hong Kong has increased from 2,340 in 2013 to 3,020 in 2023, marking a nearly 30% growth [6] - The Hong Kong government is fostering an environment conducive to biotechnology innovation through supportive policies, funding channels, and talent attraction [6]